A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Overview

This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.

The study plans to enroll approximately 90 patients with relapsed or refractory multiple myeloma at around 20 study centers. Primary objective: The objective response rate (ORR) of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma. Secondary objective: The efficacy of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma (complete response rate \[CRR\], progression - free survival \[PFS\], overall survival \[OS\], duration of response \[DOR\], time to response \[TTR\], time to progression \[TTP\], minimal residual disease - negative rate); The incidence and grade of adverse events (AE), serious adverse events (SAE), abnormal laboratory test indicators.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts